This article is more than 5 years old. Information may no longer be current.
Repeat injection for De Quervain’s tenosynovitis yielded high success rate
Click Here to Manage Email Alerts
LAS VEGAS — Although multiple, subsequent injections decreased the success rate for treatment of De Quervain’s tenosynovitis, results presented at the American Society for Surgery of the Hand showed a high rate of success with a repeat injection.
Kareem Hassan, MD, and colleagues stratified patients diagnosed with De Quervain’s tenosynovitis by therapeutic interventions, including therapy, injections and surgery.
“A failed injection was defined as an injection which was followed by a repeat injection or went on to surgery,” Hassan said in his presentation here.
Among approximately 33,000 patients diagnosed with De Quervain’s tenosynovitis, Hassan noted 17% of patients received injections, 11% underwent surgery and 5% received therapy. Women had a three-times greater risk of being diagnosed with De Quervain’s tenosynovitis compared with men, according to Hassan, and diagnosis exponentially increased with age.
“Looking at the success rate by the number of injections a patient received overall, the success rate of the first injection was approximately 68%,” Hassan said. “Success of the second injection was 61% and third injection was about 55% successful.”
Hassan noted 19.6% of patients underwent repeat injection and 11.6% of patients went on to surgery following the first injection. Patients received an average of 1.2 injections, and Hassan said there was an association between a shorter time between injection and increased failure rate.
“If the patient waited approximately 4 months between the first and second injections, however, they were about 65% successful,” Hassan said. “Patients who received only splinting or therapy were more likely to end up with surgery.” – by Casey Tingle
Reference:
Hassan K, et al. Abstract 28. Presented at: American Society for Surgery of the Hand Annual Meeting; Sept. 5-7, 2019; Las Vegas.
Disclosure: Hassan reports no relevant financial disclosures.